ANGO - AngioDynamics, Inc.
| Previous Close | 15.19 |
| Open | 15.23 |
| Bid | 15.21 x 2200 |
| Ask | 15.25 x 1000 |
| Day's Range | 15.09 - 15.29 |
| 52 Week Range | 13.72 - 25.48 |
| Volume | 25,931 |
| Avg. Volume | 284,364 |
| Market Cap | 574.832M |
| Beta (3Y Monthly) | 0.63 |
| PE Ratio (TTM) | 9.50 |
| EPS (TTM) | 1.61 |
| Earnings Date | Jan 2, 2020 - Jan 6, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.33 |
- American City Business Journals
Angio hires Fingerpaint to help bring new laser to market
The Albany region's largest medical device maker is teaming up with the area's largest advertising firm for the first time.
- GuruFocus.com
Weekly CEO Buys Highlight
CEO buys this past week include OPKO Health, Eli Lilly and Co., Wesbanco, AngioDynamics and TherapeuticsMD Continue reading...
- Simply Wall St.
Introducing AngioDynamics (NASDAQ:ANGO), The Stock That Dropped 27% In The Last Year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
- Zacks
Why Is AngioDynamics (ANGO) Up 0.9% Since Last Earnings Report?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Insider Monkey
Is AngioDynamics, Inc. (ANGO) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]
- Benzinga
The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 22) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead ...
- American City Business Journals
AngioDynamics' CFO will leave company
The company has undergone a $100 million turnaround since CEO Jim Clemmer and CFO Michael Greiner joined the business a little more than three years ago.
- Business Wire
AngioDynamics Announces Departure of CFO and Appointment of Interim CFO
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial Officer (CFO) will be departing the Company. Stephen A. Trowbridge, Senior Vice President and General Counsel, will assume the role of interim Chief Financial Officer in addition to his current responsibilities. Mr. Greiner will remain with AngioDynamics to facilitate a smooth transition of duties up to the filing of the second fiscal quarter 10-Q, and the Company has initiated a process to determine a permanent successor.
- Zacks
AngioDynamics Boosts VIT Product Portfolio With New Buyout
AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.
- American City Business Journals
Behind the deal: AngioDynamics acquired a laser startup so it can take on industry giants Medtronic and Boston Scientific
AngioDynamics CEO Jim Clemmer has spent the past two years shedding low-margin products from the Latham company's portfolio, replacing them with higher-margin emerging technology.
- Thomson Reuters StreetEvents
Edited Transcript of ANGO earnings conference call or presentation 3-Oct-19 12:00pm GMT
Q1 2020 AngioDynamics Inc Earnings Call
- Zacks
AngioDynamics (ANGO) Q1 Earnings Top, Revenues Lag Estimates
AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view.
- Zacks
Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform
Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.
- Zacks
AngioDynamics (ANGO) Q1 Earnings Beat Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of 100.00% and -2.32%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?
- American City Business Journals
AngioDynamics acquires Israeli laser startup
AngioDynamics has acquired Israeli startup Eximo Medical Ltd. to gain a foothold in a $500 million market. The transaction gives the Latham medical device maker ownership of Eximo's laser technology, which has received approval from the U.S. Food and Drug Administration to be used for treating patients with peripheral artery disease. AngioDynamics (Nasdaq: ANGO) will pay $46 million up front.
- TheStreet.com
AngioDynamics Tanks as Guidance Is Revised Lower Following Acquisition of Eximo
Shares of medical device maker AngioDynamics declined significantly Thursday after the company updated its full-year earnings guidance following an acquisition. The company announced the purchase of Israeli laser company Eximo for $46 million up front, with up to another $20 million if Eximo meets technical and revenue milestones. AngioDynamics said that it now expects earnings per share for fiscal 2020 to range between 10 cents and 15 cents a share.
- Business Wire
AngioDynamics Reports Fiscal 2020 First Quarter Financial Results
Fiscal 2020 First Quarter Highlights
- Business Wire
AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has acquired Eximo Medical, Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform for $46 million in up-front consideration with up to $20 million of contingent ...
- ACCESSWIRE
AngioDynamics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 3, 2019 / AngioDynamics, Inc. (OTC PINK: ANGO ) will be discussing their earnings results in their 2020 First Quarter Earnings to be held on October 3, 2019 at 8:00 ...
- Zacks
Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
AngioDynamics, Inc. (NASDAQ:ANGO): Are Analysts Optimistic?
AngioDynamics, Inc.'s (NASDAQ:ANGO): AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical...
- Simply Wall St.
Calculating The Intrinsic Value Of AngioDynamics, Inc. (NASDAQ:ANGO)
How far off is AngioDynamics, Inc. (NASDAQ:ANGO) from its intrinsic value? Using the most recent financial data, we'll...
